|
JPS51133489A
(en)
|
1975-05-14 |
1976-11-19 |
Tokyo Daigaku |
Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities
|
|
US4658019A
(en)
|
1979-04-26 |
1987-04-14 |
Ortho Pharmaceutical Corporation |
Complement-fixing monoclonal antibody to human T cells
|
|
US4361549A
(en)
|
1979-04-26 |
1982-11-30 |
Ortho Pharmaceutical Corporation |
Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
|
|
US4515893A
(en)
|
1979-04-26 |
1985-05-07 |
Ortho Pharmaceutical Corporation |
Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
|
|
US4221794A
(en)
|
1979-06-21 |
1980-09-09 |
Newport Pharmaceuticals International, Inc. |
Method of imparting immunomodulating and antiviral activity
|
|
US4695624A
(en)
|
1984-05-10 |
1987-09-22 |
Merck & Co., Inc. |
Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
|
|
US4882317A
(en)
|
1984-05-10 |
1989-11-21 |
Merck & Co., Inc. |
Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
|
|
NZ214503A
(en)
|
1984-12-20 |
1990-02-26 |
Merck & Co Inc |
Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
|
|
US5078998A
(en)
|
1985-08-02 |
1992-01-07 |
Bevan Michael J |
Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US4882424A
(en)
|
1987-05-11 |
1989-11-21 |
Dana-Farber Cancer Institute, Inc. |
Activation antigen
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
CA2003455C
(en)
|
1988-11-23 |
2000-02-22 |
Craig B. Thompson |
Immunotherapy involving cd28 stimulation
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
JP3485184B2
(ja)
|
1989-07-14 |
2004-01-13 |
アメリカン サイアナミド カンパニー |
インターロイキン含有安定ワクチン組成物
|
|
SE8903100D0
(sv)
|
1989-09-20 |
1989-09-20 |
Pharmacia Ab |
New pharmaceutical agent
|
|
WO1991006319A1
(en)
|
1989-10-27 |
1991-05-16 |
Arch Development Corporation |
Methods and compositions for promoting immunopotentiation
|
|
US6406696B1
(en)
|
1989-10-27 |
2002-06-18 |
Tolerance Therapeutics, Inc. |
Methods of stimulating the immune system with anti-CD3 antibodies
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
ZA91463B
(en)
|
1990-01-25 |
1992-09-30 |
Bristol Myers Squibb Co |
Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody
|
|
EP0537293A4
(en)
|
1990-07-02 |
1993-09-08 |
Bristol-Myers Company |
Ligand for cd28 receptor on b cells and methods
|
|
WO1992015671A1
(en)
|
1991-03-08 |
1992-09-17 |
Cytomed, Inc. |
Soluble cd28 proteins and methods of treatment therewith
|
|
CA2580812A1
(en)
|
1991-06-27 |
1993-01-07 |
Bristol-Myers Squibb Company |
Ctla4 receptor, fusion proteins containing it and uses thereof
|
|
US5770197A
(en)
|
1991-06-27 |
1998-06-23 |
Bristol-Myers Squibb Company |
Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
EP1488805A2
(en)
|
1992-04-07 |
2004-12-22 |
The Regents of the University of Michigan |
CD28 pathway immunoregulation
|
|
WO1993025712A1
(en)
|
1992-06-15 |
1993-12-23 |
The Regents Of The University Of California |
Screening assay for the identification of immunosuppressive drugs
|
|
WO1994023760A1
(en)
|
1993-04-14 |
1994-10-27 |
The United States Of America As Represented By The Secretary Of The Navy |
Transgenic animal model for autoimmune diseases
|
|
US20030108548A1
(en)
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
US6491916B1
(en)
|
1994-06-01 |
2002-12-10 |
Tolerance Therapeutics, Inc. |
Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
|
|
AU7107794A
(en)
|
1993-06-10 |
1995-01-03 |
Regents Of The University Of Michigan, The |
Cd28 pathway immunosuppression
|
|
CA2167091A1
(en)
|
1993-07-26 |
1995-02-02 |
Gordon J. Freeman |
B7-2: ctl a4/cd 28 counter receptor
|
|
JP3521382B2
(ja)
|
1997-02-27 |
2004-04-19 |
日本たばこ産業株式会社 |
細胞間接着及びシグナル伝達を媒介する細胞表面分子
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
US7041289B1
(en)
|
1997-12-05 |
2006-05-09 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for treating established spontaneous auto-immune diseases in mammals
|
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
US6723538B2
(en)
|
1999-03-11 |
2004-04-20 |
Micromet Ag |
Bispecific antibody and chemokine receptor constructs
|
|
EP1169038B9
(en)
|
1999-04-15 |
2013-07-10 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
AU7740600A
(en)
|
1999-10-01 |
2001-05-10 |
Biotransplant Incorporated |
Process for inducing functional tolerance to gene transfer products
|
|
AUPQ431299A0
(en)
|
1999-11-26 |
1999-12-23 |
Unisearch Limited |
Method of inducing immune tolerance
|
|
DE60037345T2
(de)
|
1999-12-10 |
2008-11-13 |
Pfizer Products Inc., Groton |
Pyrrolo(2,3-d)pyrimidin-Verbindungen
|
|
US20020006403A1
(en)
|
1999-12-14 |
2002-01-17 |
Xue-Zhong Yu |
CD28-specific antibody compositions for use in methods of immunosuppression
|
|
DE10001372A1
(de)
|
2000-01-14 |
2001-08-02 |
Deutsches Krebsforsch |
Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
|
|
US20010044416A1
(en)
|
2000-01-20 |
2001-11-22 |
Mccluskie Michael J. |
Immunostimulatory nucleic acids for inducing a Th2 immune response
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
US7395158B2
(en)
|
2000-05-30 |
2008-07-01 |
Sensys Medical, Inc. |
Method of screening for disorders of glucose metabolism
|
|
JP5184732B2
(ja)
|
2000-06-19 |
2013-04-17 |
ベス イスラエル デアコネス メディカル センター |
Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法
|
|
ATE423120T1
(de)
|
2000-06-26 |
2009-03-15 |
Pfizer Prod Inc |
Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
|
|
AU2001295503A1
(en)
|
2000-08-22 |
2002-03-04 |
Micromet Ag |
Composition for the elimination of autoreactive b-cells
|
|
EP2070921A1
(en)
|
2000-11-07 |
2009-06-17 |
Novartis Ag |
Indolylmaleimide derivatives as protein kinase c inhibitors
|
|
US7304033B2
(en)
|
2001-05-23 |
2007-12-04 |
Bristol-Myers Squibb Company |
Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
|
|
CN1195779C
(zh)
|
2001-05-24 |
2005-04-06 |
中国科学院遗传与发育生物学研究所 |
抗人卵巢癌抗人cd3双特异性抗体
|
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
GB2380127A
(en)
|
2001-09-26 |
2003-04-02 |
Isis Innovation |
Treatment of chronic joint inflammation
|
|
PY0228255A
(es)
|
2001-12-06 |
2004-06-01 |
Pfizer Prod Inc |
Compuestos cristalinos novedosos
|
|
AU2003208839A1
(en)
|
2002-02-13 |
2003-09-04 |
Micromet Ag |
De-immunized (poly)peptide constructs
|
|
US20030216551A1
(en)
|
2002-03-08 |
2003-11-20 |
Diabetogen Biosciences Inc. |
Fully human anti-CD3 monoclonal antibodies
|
|
KR100517056B1
(ko)
|
2002-04-15 |
2005-09-27 |
재단법인 목암생명공학연구소 |
하이드록실 페닐 유도체, 그의 제조방법 및 그를 포함하는약학적 조성물
|
|
WO2003102132A2
(en)
|
2002-04-26 |
2003-12-11 |
Genetech, Inc. |
Non-affinity purification of proteins
|
|
DE60329724D1
(de)
|
2002-06-07 |
2009-11-26 |
Waratah Pharmaceuticals Inc |
Methoden und Kompositionen um Diabetes zu behandeln
|
|
EP1837031B1
(en)
|
2002-06-07 |
2009-10-14 |
Waratah Pharmaceuticals, Inc. |
Compositions and methods for treating diabetes
|
|
EP1515749B1
(en)
|
2002-06-14 |
2012-08-15 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a glp-1 compound
|
|
US20040037826A1
(en)
|
2002-06-14 |
2004-02-26 |
Michelsen Birgitte Koch |
Combined use of a modulator of CD3 and a GLP-1 compound
|
|
WO2003105896A1
(en)
|
2002-06-14 |
2003-12-24 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a beta cell resting compound
|
|
US20030235583A1
(en)
|
2002-06-14 |
2003-12-25 |
Jeppe Sturis |
Combined use of a modulator of CD3 and a beta cell resting compound
|
|
EP1400534B1
(en)
|
2002-09-10 |
2015-10-28 |
Affimed GmbH |
Human CD3-specific antibody with immunosuppressive properties
|
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
|
AU2003283004A1
(en)
|
2002-10-22 |
2004-05-13 |
Waratah Pharmaceuticals, Inc. |
Treatment of diabetes
|
|
US7438907B2
(en)
|
2002-11-15 |
2008-10-21 |
Genmab A/S |
Human monoclonal antibodies against CD25
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
US20060235201A1
(en)
|
2003-02-06 |
2006-10-19 |
Roman Kischel |
Enduring T cell response
|
|
US7196093B2
(en)
|
2003-04-09 |
2007-03-27 |
General Atomics |
Reversible inhibitors of SAH hydrolase and uses thereof
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
RU2005137325A
(ru)
|
2003-05-31 |
2006-09-10 |
Микромет Аг (De) |
Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам
|
|
JP2008501621A
(ja)
|
2003-05-31 |
2008-01-24 |
マイクロメット アクツィエン ゲゼルシャフト |
Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
|
|
JP2006526414A
(ja)
|
2003-06-02 |
2006-11-24 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
脱免疫化抗ｃｄ３抗体
|
|
WO2005007628A1
(en)
|
2003-07-11 |
2005-01-27 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives as cannabinoid receptor modulators
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
US7326706B2
(en)
|
2003-08-15 |
2008-02-05 |
Bristol-Myers Squibb Company |
Pyrazine modulators of cannabinoid receptors
|
|
WO2005037199A2
(en)
|
2003-10-10 |
2005-04-28 |
Bristol-Myers Squibb Company |
Pyrazole derivatives as cannabinoid receptor modulators
|
|
US20050176028A1
(en)
|
2003-10-16 |
2005-08-11 |
Robert Hofmeister |
Deimmunized binding molecules to CD3
|
|
MXPA06004035A
(es)
|
2003-10-16 |
2006-08-31 |
Micromet Ag |
Aglutinantes cd3 de-inmunizados multi-especificos.
|
|
CA2542777C
(en)
|
2003-10-23 |
2016-02-02 |
Chiron Corporation |
Stabilised compositions
|
|
US20070053954A1
(en)
|
2003-10-24 |
2007-03-08 |
Rowe Stephen C |
Macromer-melt formulations
|
|
WO2005040163A1
(en)
|
2003-10-28 |
2005-05-06 |
Dr. Reddy's Laboratories Ltd |
Heterocyclic compounds that block the effects of advanced glycation end products (age)
|
|
US7883703B2
(en)
|
2003-11-14 |
2011-02-08 |
The Brigham And Women's Hospital, Inc. |
Methods of modulating immunity
|
|
US20050147581A1
(en)
|
2003-11-19 |
2005-07-07 |
The Board Of Trustees Of The University Of Illinois |
Macromolecular drug complexes having improved stability and therapeutic use of the same
|
|
US10000574B2
(en)
|
2003-11-28 |
2018-06-19 |
Amgen Research (Munich) Gmbh |
Compositions comprising polypeptides
|
|
WO2005063761A1
(en)
|
2003-12-19 |
2005-07-14 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
|
DK1697371T3
(da)
|
2003-12-19 |
2007-09-17 |
Bristol Myers Squibb Co |
Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
EP1725254A4
(en)
|
2004-02-04 |
2008-02-13 |
Univ Columbia |
ANTI-CD3 IMMUNOTHERAPY AND SPECIFIC ANTIGENS FOR THE TREATMENT OF AUTOIMMUNITY
|
|
EP1716178B1
(en)
|
2004-02-16 |
2010-08-11 |
Micromet AG |
Less immunogenic binding molecules
|
|
ES2384134T3
(es)
|
2004-02-20 |
2012-06-29 |
Develogen Aktiengesellschaft |
Uso de productos proteínicos secretados para prevención y tratamiento de enfermedades pancreáticas y/u obesidad y/o síndrome metabólico
|
|
US20050250691A1
(en)
|
2004-05-10 |
2005-11-10 |
Diamyd Therapeutics Ab |
Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
|
|
EP1755631A2
(en)
|
2004-03-03 |
2007-02-28 |
Diamyd Medical AB |
Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
|
|
US7850962B2
(en)
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
|
US20060194725A1
(en)
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
US7592313B2
(en)
|
2004-05-17 |
2009-09-22 |
Board Of Trustees Of The University Of Illinois |
Method of stimulating proliferation of regulatory T cells in a diabetic mammal
|
|
CA2569509C
(en)
|
2004-06-03 |
2014-08-12 |
Novimmune S.A. |
Anti-cd3 antibodies and methods of use thereof
|
|
EP1765873A4
(en)
|
2004-07-01 |
2009-07-01 |
Waratah Pharmaceuticals Inc |
COMBINED USE OF CD3 AGONIST AND GASTRIN FOR THE TREATMENT OF DIABETES
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
JP2008511559A
(ja)
|
2004-08-30 |
2008-04-17 |
バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト |
Ｔ−細胞を調節することによるｈｉｖ感染の治療
|
|
WO2006033811A2
(en)
|
2004-09-03 |
2006-03-30 |
The Trustees Of Columbia University In The City Of New York |
Ilt3 polypeptides and uses thereof
|
|
US20070264229A1
(en)
|
2004-09-13 |
2007-11-15 |
Strominger Jack L |
Peptides for Treatment of Autoimmune Disease
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
JPWO2006057152A1
(ja)
|
2004-11-08 |
2008-06-05 |
小野薬品工業株式会社 |
タンパク質分解酵素阻害化合物からなる糖尿病治療剤
|
|
DE602005022928D1
(de)
|
2004-11-30 |
2010-09-23 |
Abgenix Inc |
Antikörper gegen gpnmb und ihre verwendungen
|
|
AU2006209837A1
(en)
|
2005-02-04 |
2006-08-10 |
Dow Agrosciences, Llc |
Anti-T cell and autoantigen treatment of autoimmune disease
|
|
US20090142338A1
(en)
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
|
EP1858545A2
(en)
|
2005-03-04 |
2007-11-28 |
Curedm Inc. |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
|
JP2008535841A
(ja)
|
2005-04-06 |
2008-09-04 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ｃｔｌａ４変異分子によるグラフト移植に関連する免疫不全の治療方法
|
|
US20130039861A1
(en)
|
2005-04-06 |
2013-02-14 |
Immunomedics, Inc. |
Dye Conjugated Peptides for Fluorescent Imaging
|
|
US20080207594A1
(en)
|
2005-05-04 |
2008-08-28 |
Davelogen Aktiengesellschaft |
Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
|
|
EP1879591B8
(en)
|
2005-05-04 |
2012-04-04 |
DeveloGen Aktiengesellschaft |
Use of azapaullones for preventing and treating pancreatic autoimmune disorders
|
|
EP1883417A2
(en)
|
2005-05-25 |
2008-02-06 |
Curedm Inc. |
Peptides, derivatives and analogs thereof, and methods of using same
|
|
WO2007009064A2
(en)
|
2005-07-11 |
2007-01-18 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
CN101309703A
(zh)
|
2005-09-12 |
2008-11-19 |
诺维莫尼公司 |
抗cd3抗体组合物
|
|
US20070190052A1
(en)
|
2005-09-14 |
2007-08-16 |
The Trustees Of Columbia University In The City Of New York |
Regulatory CD8cells induced with anti-CD3 antibody
|
|
WO2007038687A2
(en)
|
2005-09-27 |
2007-04-05 |
Aciont, Inc. |
Ocular administration of immunosuppressive agents
|
|
ES2405552T3
(es)
|
2005-11-29 |
2013-05-31 |
Actogenix N.V. |
Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
|
|
US8466263B2
(en)
|
2005-12-02 |
2013-06-18 |
Dana-Farber Cancer Institute, Inc. |
Carbonic anhydrase IX (G250) anitbodies
|
|
WO2007067683A2
(en)
|
2005-12-08 |
2007-06-14 |
University Of Louisville Research Foundation, Inc. |
Methods and compositions for expanding t regulatory cells
|
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
|
HRP20150175T1
(en)
|
2005-12-16 |
2015-03-27 |
Amgen Research (Munich) Gmbh |
Means and methods for the treatment of tumorous diseases
|
|
JP5399712B2
(ja)
|
2005-12-21 |
2014-01-29 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
可溶性ｃｅａに対する抵抗性を有する医薬組成物
|
|
RU2008129827A
(ru)
|
2005-12-21 |
2010-01-27 |
МЕДИММЬЮН, ЭлЭлСи (US) |
МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
|
|
WO2007084775A2
(en)
|
2006-01-20 |
2007-07-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for modulation of suppressor t cell activation
|
|
GB0605702D0
(en)
|
2006-03-21 |
2006-05-03 |
Biotransformations Ltd |
Materials and methods for immune cell stimulation
|
|
WO2007117600A2
(en)
|
2006-04-07 |
2007-10-18 |
Macrogenics, Inc. |
Combination therapy for treating autoimmune diseases
|
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
諾華公司 |
吡咯并嘧啶化合物及其用途
|
|
EP2433650A3
(en)
|
2006-06-06 |
2012-12-19 |
Tolerrx Inc. |
Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
|
|
SG177907A1
(en)
|
2006-06-14 |
2012-02-28 |
Macrogenics Inc |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
EP1880729A1
(en)
|
2006-07-20 |
2008-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of soluble CD160 to suppress immunity
|
|
US20080026378A1
(en)
|
2006-07-28 |
2008-01-31 |
Gian Franco Bottazzo |
Prediction and prophylactic treatment of type 1 diabetes
|
|
JP2010502224A
(ja)
|
2006-09-08 |
2010-01-28 |
アボット・ラボラトリーズ |
インターロイキン１３結合タンパク質
|
|
ES2651268T3
(es)
|
2006-09-12 |
2018-01-25 |
Beth Israel Deaconess Medical Center, Inc. |
Composiciones que contienen alfa-1-antitripsina y métodos para su uso
|
|
CN101164538B
(zh)
|
2006-10-16 |
2011-12-14 |
中国医学科学院基础医学研究所 |
羧胺三唑类化合物及其盐在制备治疗疼痛性疾病和/或炎症性疾病的药物中的应用
|
|
US8785400B2
(en)
|
2006-11-22 |
2014-07-22 |
Curedm Group Holdings, Llc |
Methods and compositions relating to islet cell neogenesis
|
|
CN101678022A
(zh)
|
2006-12-21 |
2010-03-24 |
弗特克斯药品有限公司 |
可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
|
|
CA2673470A1
(en)
|
2006-12-21 |
2008-07-03 |
Macrogenics, Inc. |
Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
US8398956B2
(en)
|
2007-01-11 |
2013-03-19 |
Immunomedics, Inc. |
In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
|
|
WO2008093246A2
(en)
|
2007-02-02 |
2008-08-07 |
Vegenics Limited |
Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
|
|
US20100129361A1
(en)
|
2007-05-01 |
2010-05-27 |
The Brigham And Women's Hospital |
Immunosuppression with antibody against itm2a
|
|
US20110020269A1
(en)
|
2007-05-08 |
2011-01-27 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for modifying t cell immune responses and inflammation
|
|
US20110300142A1
(en)
|
2007-05-25 |
2011-12-08 |
Salford Leif G |
Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
|
|
US20090324609A1
(en)
|
2007-08-09 |
2009-12-31 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
|
DK2193142T3
(da)
|
2007-08-30 |
2015-04-20 |
Curedm Group Holdings Llc |
Præparater og fremgangsmåder til anvendelse af pro-øcellepeptider og analoger dertil
|
|
WO2009070642A1
(en)
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
US8420081B2
(en)
|
2007-11-30 |
2013-04-16 |
Abbvie, Inc. |
Antibody formulations and methods of making same
|
|
EP2242504B1
(en)
|
2008-01-09 |
2021-07-14 |
The Schepens Eye Research Institute, Inc. |
Therapeutic compositions for treatment of ocular inflammatory disorders
|
|
US8025597B2
(en)
|
2008-02-20 |
2011-09-27 |
Shimano Inc. |
Bicycle component position correcting device
|
|
WO2009113083A1
(en)
|
2008-03-14 |
2009-09-17 |
Biocon Limited |
A monoclonal antibody and a method thereof
|
|
CA2720682A1
(en)
|
2008-04-25 |
2009-10-29 |
Zymogenetics, Inc. |
Levels of bcma protein expression on b cells and use in diagnostic methods
|
|
US20100260668A1
(en)
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
AU2009303318B2
(en)
|
2008-10-10 |
2016-06-30 |
Aptevo Research And Development Llc |
TCR complex immunotherapeutics
|
|
PL2918604T3
(pl)
|
2008-11-07 |
2018-05-30 |
Amgen Research (Munich) Gmbh |
Leczenie pediatrycznej ostrej białaczki limfoblastycznej
|
|
KR101695327B1
(ko)
|
2008-11-07 |
2017-01-11 |
암젠 리서치 (뮌헨) 게엠베하 |
급성 림프구성 백혈병의 치료방법
|
|
US9452227B2
(en)
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
|
WO2010065491A2
(en)
|
2008-12-01 |
2010-06-10 |
Carolus Therapeutics, Inc. |
Methods of treating inflammatory disorders
|
|
US8530629B2
(en)
|
2009-01-30 |
2013-09-10 |
Ab Biosciences, Inc. |
Lowered affinity antibodies and uses therefor
|
|
EP2408468B1
(en)
|
2009-03-19 |
2014-04-30 |
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. |
USE OF NKp46 FOR PREVENTING TYPE 1 DIABETES
|
|
AR076508A1
(es)
|
2009-05-01 |
2011-06-15 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
|
WO2011011706A2
(en)
|
2009-07-24 |
2011-01-27 |
The Johns Hopkins University |
Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
|
|
WO2011028811A2
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
KR20120104542A
(ko)
|
2009-10-15 |
2012-09-21 |
아보트 러보러터리즈 |
Ｉｌ?１ 결합 단백질
|
|
CA2778334A1
(en)
|
2009-10-20 |
2011-04-28 |
Charlotte Mckee |
Anti-cd3 antibody dosing in autoimmune disease
|
|
CA2778331A1
(en)
|
2009-10-20 |
2011-04-28 |
Aoife Brennan |
Methods of using anti-cd3 antibodies to prevent weight gain
|
|
RS54655B2
(sr)
|
2009-10-27 |
2021-04-29 |
Amgen Res Munich Gmbh |
Dozni režim za primenu cd19xcd3 bispecifičnog antitela
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US10813917B2
(en)
|
2009-12-11 |
2020-10-27 |
Medregen, Llc |
Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
|
|
US20110165161A1
(en)
|
2009-12-23 |
2011-07-07 |
Shih-Yao Lin |
Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
|
|
CA2785907A1
(en)
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Ron binding constructs and methods of use thereof
|
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
|
JP2013528357A
(ja)
|
2010-03-29 |
2013-07-11 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
US8557961B2
(en)
|
2010-04-02 |
2013-10-15 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
|
KR20130010123A
(ko)
|
2010-04-07 |
2013-01-25 |
아비에 인코포레이티드 |
ＴＮＦ-α 결합 단백질
|
|
EP2556161A4
(en)
|
2010-04-09 |
2013-11-06 |
Gen Hospital Corp |
METHOD FOR TREATING AUTOIMMUNE DISEASES
|
|
KR20130066626A
(ko)
|
2010-04-29 |
2013-06-20 |
나스벡스 엘티디. |
항ｃｄ3 면역 분자 요법을 사용하여 간염을 치료하는 방법 및 이를 위한 조성물
|
|
AR081246A1
(es)
|
2010-05-14 |
2012-07-18 |
Abbott Lab |
Proteinas de union a il-1
|
|
EP2580593A4
(en)
|
2010-06-10 |
2014-04-16 |
Myra Lipes |
DIAGNOSIS OF MYOCARDIAL AUTOIMMUNITY IN HEART DISEASES
|
|
EP3323830B1
(en)
|
2010-06-19 |
2023-08-23 |
Memorial Sloan-Kettering Cancer Center |
Anti-gd2 antibodies
|
|
EP2585828A4
(en)
|
2010-06-25 |
2014-03-12 |
Glaxo Group Ltd |
METHOD FOR THE TREATMENT OF PATIENTS WITH IMMUNE SYSTEM DISEASES
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US20120045435A1
(en)
|
2010-08-18 |
2012-02-23 |
Theresa Deisher |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
|
US20130225427A1
(en)
|
2010-09-08 |
2013-08-29 |
Sanford-Burnham Medical Research Institute |
Method for prediction of response to immune mediated disease therapeutics
|
|
US20120088678A1
(en)
|
2010-09-08 |
2012-04-12 |
Sanford-Burnham Medical Research Institute |
Method for prediction of response to rheumatoid arthritis therapeutics
|
|
DK2621282T3
(da)
|
2010-09-28 |
2020-05-04 |
Univ California |
Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
|
|
CN103459425B
(zh)
|
2010-10-27 |
2015-11-25 |
安进研发（慕尼黑）股份有限公司 |
用于治疗dlbcl的组合物
|
|
UY33707A
(es)
|
2010-11-04 |
2012-05-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EA026075B1
(ru)
|
2010-11-10 |
2017-02-28 |
Эмджен Рисерч (Мьюник) Гмбх |
Предотвращение неблагоприятных эффектов, вызванных cd3-специфическими связывающими доменами
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
AR084210A1
(es)
|
2010-12-08 |
2013-05-02 |
Abbott Lab |
PROTEINAS DE UNION AL TNF-a
|
|
UY33826A
(es)
|
2010-12-22 |
2012-07-31 |
Abbott Lab |
Proteínas de unión con dominios trivariables y sus usos
|
|
US20120201746A1
(en)
|
2010-12-22 |
2012-08-09 |
Abbott Laboratories |
Half immunoglobulin binding proteins and uses thereof
|
|
MX341578B
(es)
|
2011-02-08 |
2016-08-25 |
Abbvie Inc |
Tratamiento de la osteoartritis y del dolor.
|
|
US20140147413A1
(en)
|
2011-02-28 |
2014-05-29 |
Dong Feng Chen |
Therapies That Target Autoimmunity For Treating Glaucoma And Optic Neuropathy
|
|
TR201909840T4
(tr)
|
2011-03-11 |
2019-07-22 |
Beth Israel Deaconess Medical Ct Inc |
Anti-CD40 antikorları ve kullanımları.
|
|
EP2691515A2
(en)
|
2011-03-31 |
2014-02-05 |
President and Fellows of Harvard College |
A unique population of regulatory t cells that regulate tissue regeneration and wound healing
|
|
US10239952B2
(en)
|
2011-04-01 |
2019-03-26 |
Memorial Sloan Kettering Cancer Center |
Anti-WT1/HLA bi-specific antibody
|
|
KR102345943B1
(ko)
|
2011-04-28 |
2021-12-31 |
암젠 리서치 (뮌헨) 게엠베하 |
잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법
|
|
KR102060389B1
(ko)
|
2011-05-21 |
2019-12-31 |
마크로제닉스, 인크. |
사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
|
|
WO2012173819A2
(en)
|
2011-06-14 |
2012-12-20 |
Mayo Foundation For Medical Education And Research |
Anti-cd3 therapies
|
|
WO2012178160A2
(en)
|
2011-06-23 |
2012-12-27 |
University Of Florida Research Foundation, Inc. |
Materials and methods for modulating immune responses
|
|
US20140242081A1
(en)
|
2011-07-18 |
2014-08-28 |
Micromet Ag |
Dosing regimens for treatment of cea-expressing cancers
|
|
CN102898527B
(zh)
|
2011-07-25 |
2016-12-21 |
三星电子株式会社 |
融合蛋白、药物组合物及预防或治疗癌症的方法
|
|
ES2893855T3
(es)
|
2011-08-11 |
2022-02-10 |
Ono Pharmaceutical Co |
Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
|
|
US8932586B2
(en)
|
2011-09-06 |
2015-01-13 |
Intrexon Corporation |
Modified forms of Pseudomonas exotoxin A
|
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
|
JP2014526509A
(ja)
|
2011-09-13 |
2014-10-06 |
バイオメッド バレー ディスカバリーズ，インコーポレイティド |
代謝障害を治療するための組成物および方法
|
|
HK1201466A1
(en)
|
2011-09-21 |
2015-09-04 |
干细胞医药有限公司 |
Beta-lactam compounds for treating diabetes
|
|
WO2013048243A1
(en)
|
2011-09-29 |
2013-04-04 |
Apo-T B.V. |
Multi-specific binding molecules targeting aberrant cells
|
|
CA2841867A1
(en)
|
2011-10-03 |
2013-04-11 |
Celeste Aida S. Regino |
Dye conjugated peptides for fluorescent imaging
|
|
BR112014010580B1
(pt)
|
2011-11-04 |
2021-01-12 |
Zymeworks, Inc. |
constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
|
|
US20140212425A1
(en)
|
2011-12-05 |
2014-07-31 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
|
WO2013093045A2
(en)
|
2011-12-22 |
2013-06-27 |
Medizinische Universität Wien |
Cyclotides as immunosuppressive agents
|
|
CN113699105A
(zh)
|
2011-12-23 |
2021-11-26 |
人类起源公司 |
包含脱细胞并再群体化的胎盘血管支架的类器官
|
|
CA2861003C
(en)
|
2012-01-13 |
2023-03-28 |
Julius-Maximilians-Universitat Wurzburg |
Dual antigen-induced bipartite functional complementation
|
|
GB201201314D0
(en)
|
2012-01-26 |
2012-03-07 |
Isis Innovation |
Composition
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
|
CN106668852B
(zh)
|
2012-04-13 |
2020-12-25 |
艾棣维欣(苏州)生物制药有限公司 |
一种治疗和/或预防ⅰ型糖尿病的组合物及其应用
|
|
CN107252492A
(zh)
|
2012-04-18 |
2017-10-17 |
诺格尔制药有限公司 |
治疗糖尿病和/或促进胰岛移植后存活的方法
|
|
CN104363919A
(zh)
|
2012-06-01 |
2015-02-18 |
Ibc药品公司 |
具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
|
|
EP2892924B1
(en)
|
2012-06-14 |
2020-11-25 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
WO2013188693A1
(en)
|
2012-06-15 |
2013-12-19 |
Imaginab, Inc. |
Antigen binding constructs to cd3
|
|
KR20150033703A
(ko)
|
2012-06-27 |
2015-04-01 |
오르반 바이오테크 엘엘씨 |
당뇨병 치료를 위한 ctla4 융합 단백질
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
CN104379169A
(zh)
|
2012-08-14 |
2015-02-25 |
Ibc药品公司 |
用于治疗疾病的t-细胞重定向双特异性抗体
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
US9511110B2
(en)
|
2012-09-27 |
2016-12-06 |
Perle Bioscience, Inc. |
Generation of new pancreatic beta cells
|
|
US8808689B1
(en)
|
2012-09-27 |
2014-08-19 |
Perle Bioscience, Inc. |
Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent
|
|
JP6499079B2
(ja)
|
2012-11-13 |
2019-04-10 |
バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ |
クローディンを発現するガン疾患を処置するための剤
|
|
US9562110B2
(en)
|
2012-11-21 |
2017-02-07 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
US10130632B2
(en)
|
2012-11-27 |
2018-11-20 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for treating renal disease
|
|
US10329350B2
(en)
|
2012-12-26 |
2019-06-25 |
Industrial Technology Research Institute |
Method for producing a multivalent fab fragment with collagen-like peptide
|
|
CN105008918A
(zh)
|
2013-01-04 |
2015-10-28 |
西托姆克斯治疗公司 |
用于检测生物系统中的蛋白酶活性的组合物和方法
|
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
US20140234405A1
(en)
|
2013-02-15 |
2014-08-21 |
Claresa Levetan |
Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
|
|
US20140235552A1
(en)
|
2013-02-15 |
2014-08-21 |
Claresa Levetan |
Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
|
|
CN105358678A
(zh)
|
2013-03-08 |
2016-02-24 |
密苏里大学董事会 |
治疗和/或预防1型糖尿病的方法和组合物
|
|
TWI832345B
(zh)
|
2013-03-14 |
2024-02-11 |
美商安美基公司 |
用於增加重組蛋白質之甘露糖含量之方法
|
|
US9732150B2
(en)
|
2013-03-14 |
2017-08-15 |
Alderbio Holdings Llc |
Therapeutic use of antibodies to HGF
|
|
MX384232B
(es)
|
2013-03-14 |
2025-03-14 |
Jerome J Schentag |
Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.
|
|
CN105530959B
(zh)
|
2013-03-15 |
2021-09-17 |
纪念斯隆-凯特琳癌症中心 |
多聚化技术
|
|
WO2014145873A2
(en)
|
2013-03-15 |
2014-09-18 |
Epigen Biosciences, Inc. |
Heterocyclic compounds useful in the treatment of disease
|
|
RU2680267C2
(ru)
|
2013-03-15 |
2019-02-19 |
Мемориал Слоан Кеттеринг Кэнсер Сентер |
Высокоаффинные антитела к gd2
|
|
PL2970449T3
(pl)
|
2013-03-15 |
2020-04-30 |
Amgen Research (Munich) Gmbh |
Jednołańcuchowe cząsteczki wiążące zawierające N-końcowy ABP
|
|
GB201305714D0
(en)
|
2013-03-28 |
2013-05-15 |
Ucl Business Plc |
Method
|
|
WO2014165818A2
(en)
|
2013-04-05 |
2014-10-09 |
T Cell Therapeutics, Inc. |
Compositions and methods for preventing and treating prostate cancer
|
|
CA2812016A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
JP6438457B2
(ja)
|
2013-04-16 |
2018-12-12 |
オルブセン セラピューティクス リミテッド |
シンデカン−２の医療用途
|
|
CN105658217B
(zh)
|
2013-04-29 |
2021-03-19 |
约翰霍普金斯大学 |
经由自体干细胞动员的创伤愈合
|
|
WO2015172800A1
(en)
|
2014-05-12 |
2015-11-19 |
Numab Ag |
Novel multispecific molecules and novel treatment methods based on such multispecific molecules
|
|
SG11201509361TA
(en)
|
2013-05-28 |
2015-12-30 |
Numab Ag |
Novel antibodies
|
|
PT3024484T
(pt)
|
2013-07-23 |
2018-10-24 |
Novaliq Gmbh |
Composições de anticorpo estabilizadas
|
|
CN105722859B
(zh)
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
CN104342453A
(zh)
|
2013-08-06 |
2015-02-11 |
深圳先进技术研究院 |
含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
RU2671089C2
(ru)
|
2013-09-16 |
2018-10-29 |
Хельмхольтц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) |
Би- или полиспецифические полипептиды, связывающие поверхностные антигены иммунных эффекторных клеток и антигены hbv для лечения инфекций bv и ассоциированных с ними состояний
|
|
GB201317928D0
(en)
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
JP2016538275A
(ja)
|
2013-11-04 |
2016-12-08 |
グレンマーク ファーマシューティカルズ， エセ．アー． |
Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
|
|
EP3068891A1
(en)
|
2013-11-13 |
2016-09-21 |
Aequus Biopharma Inc. |
Engineered glycoproteins and uses thereof
|
|
WO2015073833A1
(en)
|
2013-11-15 |
2015-05-21 |
Pharmacyclics, Inc. |
Methods for delaying or preventing the onset of type 1 diabetes
|
|
US20160287622A1
(en)
|
2013-11-18 |
2016-10-06 |
Massachusetts Institute Of Technology |
Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction
|
|
EP2878308B1
(en)
|
2013-12-02 |
2018-10-31 |
Thomas Harder |
Agents and methods for the suppression of T cell activation
|
|
SI3077395T1
(en)
|
2013-12-05 |
2018-03-30 |
Pfizer Inc. |
Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
|
|
IL263466B2
(en)
|
2013-12-17 |
2023-10-01 |
Genentech Inc |
Anti-CD3 antibodies and methods of using them
|
|
SG11201605203UA
(en)
|
2013-12-24 |
2016-07-28 |
Argen X N V |
Fcrn antagonists and methods of use
|
|
US10519251B2
(en)
|
2013-12-30 |
2019-12-31 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
WO2015103319A1
(en)
|
2013-12-31 |
2015-07-09 |
Heron Therapeutics, Inc. |
Polymer-based compositions for extended release of proteins
|
|
CA2936244A1
(en)
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
|
DK3105252T3
(da)
|
2014-02-12 |
2019-10-14 |
Michael Uhlin |
Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
|
|
US20160039876A1
(en)
|
2014-03-28 |
2016-02-11 |
Claresa Levetan |
Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
|
|
PL3129483T3
(pl)
|
2014-04-08 |
2019-05-31 |
Fraunhofer Ges Forschung |
Terapia skojarzona do leczenia chorób autoimmunologicznych
|
|
KR101628872B1
(ko)
|
2014-05-28 |
2016-06-09 |
주식회사 레고켐 바이오사이언스 |
자가-희생 기를 포함하는 화합물
|
|
EA035419B9
(ru)
|
2014-05-29 |
2020-08-07 |
Мэкроудженикс, Инк. |
Триспецифичные связывающие молекулы и способы их применения
|
|
EP2955196A1
(en)
|
2014-06-10 |
2015-12-16 |
Effimune |
Antibodies directed against CD127
|
|
US20170218091A1
(en)
|
2014-07-03 |
2017-08-03 |
Abbvie Inc. |
Monovalent binding proteins
|
|
US9611325B2
(en)
|
2014-07-21 |
2017-04-04 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody HER2xCD3
|
|
CN106999556B
(zh)
|
2014-07-21 |
2021-07-30 |
武汉友芝友生物制药有限公司 |
细胞因子诱导的杀伤细胞的双特异性抗体介导的癌症治疗
|
|
US9777073B2
(en)
|
2014-07-21 |
2017-10-03 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody EpCAM×CD3
|
|
JP6871155B2
(ja)
|
2014-07-25 |
2021-05-12 |
メモリアル スローン ケタリング キャンサー センター |
二重特異性ｈｅｒ２及びｃｄ３結合分子
|
|
US11820832B2
(en)
|
2014-07-25 |
2023-11-21 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
|
GB201413240D0
(en)
|
2014-07-25 |
2014-09-10 |
Hansa Medical Ab |
Method
|
|
JP6431721B2
(ja)
|
2014-08-13 |
2018-11-28 |
学校法人大阪医科薬科大学 |
劇症１型糖尿病の検出方法及びバイオマーカー並びにキット
|
|
CN106573006A
(zh)
|
2014-08-21 |
2017-04-19 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为药物的rip1激酶抑制剂杂环酰胺
|
|
KR102485788B1
(ko)
|
2014-08-27 |
2023-01-09 |
메모리얼 슬로안 케터링 캔서 센터 |
항체, 조성물 및 용도
|
|
ES2845656T3
(es)
|
2014-09-18 |
2021-07-27 |
Immucor Gti Diagnostics Inc |
Kits y procedimientos para detectar anticuerpos anticélulas endoteliales en rechazo de aloinjertos
|
|
EP3194439B1
(en)
|
2014-09-19 |
2022-01-19 |
Siwa Corporation |
Anti-age antibodies for treating inflammation and auto-immune disorders
|
|
WO2016061201A1
(en)
|
2014-10-14 |
2016-04-21 |
The Brigham And Women's Hospital, Inc. |
Nanoparticles and methods of use
|
|
US10583091B2
(en)
|
2014-10-23 |
2020-03-10 |
The Brigham And Women's Hospital, Inc. |
Amphiphile-polymer particles
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
US11091547B2
(en)
|
2014-11-12 |
2021-08-17 |
Memorial Sloan Kettering Cancer Center |
Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
|
|
CN107278203B
(zh)
|
2014-12-05 |
2020-05-19 |
阵列生物制药公司 |
作为JANUS激酶抑制剂的4,6-取代的吡唑并[1,5-a]吡嗪
|
|
WO2016089610A1
(en)
|
2014-12-06 |
2016-06-09 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bispecific antibody for cancer immunotherapy
|
|
KR102654033B1
(ko)
|
2014-12-08 |
2024-04-02 |
1글로브 바이오메디칼 씨오., 엘티디. |
가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도
|
|
MX384198B
(es)
|
2014-12-19 |
2025-03-14 |
Chiome Bioscience Inc |
Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.
|
|
US10022347B2
(en)
|
2015-01-07 |
2018-07-17 |
The United States Of America, As Represented By The Secretary Of The Navy |
Compositions and methods for diagnosis and treatment of metabolic syndrome
|
|
CN120988137A
(zh)
|
2015-01-23 |
2025-11-21 |
赛诺菲 |
抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
|
|
KR102763121B1
(ko)
|
2015-02-06 |
2025-02-04 |
내셔널 유니버시티 오브 싱가포르 |
치료적 면역 세포의 효능의 향상 방법
|
|
JP6649941B2
(ja)
|
2015-02-16 |
2020-02-19 |
株式会社ファーマフーズ |
Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
|
|
KR102624023B1
(ko)
|
2015-02-24 |
2024-01-11 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
결합-촉발된 전사 스위치 및 이들의 이용 방법
|
|
GB201503500D0
(en)
|
2015-03-02 |
2015-04-15 |
Ucl Business Plc |
Cell
|
|
EP3267969A1
(en)
|
2015-03-09 |
2018-01-17 |
King's College London |
Combination therapy with rar alpha agonists for enhancing th1 response
|
|
CA2978253A1
(en)
|
2015-03-09 |
2016-09-15 |
Argenx Bvba |
Methods of reducing serum levels of fc-containing agents using fcrn antagonists
|
|
US10772917B2
(en)
|
2015-03-11 |
2020-09-15 |
Ccs Ventures Limited |
Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (T2D)
|
|
WO2016154047A2
(en)
|
2015-03-20 |
2016-09-29 |
Memorial Sloan-Kettering Cancer Center |
Monoclonal antigen-binding proteins to intracellular oncogene products
|
|
US10378055B2
(en)
|
2015-04-08 |
2019-08-13 |
City Of Hope |
Methods and compositions for measuring beta cell death
|
|
US11000603B2
(en)
|
2015-04-14 |
2021-05-11 |
Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. |
Multi-specific binding conjugate, related pharmaceutical compositions and use
|
|
US10449209B2
(en)
|
2015-04-29 |
2019-10-22 |
Arterez, Llc |
Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
|
|
HRP20200439T1
(hr)
|
2015-04-30 |
2020-06-12 |
Psioxus Therapeutics Limited |
Onkolitički adenovirus koji kodira protein b7
|
|
EP3288981A1
(en)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
BR112017023692A2
(pt)
|
2015-05-01 |
2018-07-17 |
The Regents Of The University Of California |
moléculas imunoterapêuticas glican-dependentes
|
|
US9708412B2
(en)
|
2015-05-21 |
2017-07-18 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
CN107810198B
(zh)
|
2015-05-29 |
2021-09-03 |
艾伯维公司 |
抗cd40抗体及其用途
|
|
AU2016274989A1
(en)
|
2015-06-12 |
2017-11-02 |
Immunomedics, Inc. |
Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
|
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
US20190135894A1
(en)
|
2015-06-25 |
2019-05-09 |
iCell Gene Therapeuticics LLC |
COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP3322715B1
(en)
|
2015-07-14 |
2023-10-18 |
BioNTech SE |
Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
|
|
EP3322735A4
(en)
|
2015-07-15 |
2019-03-13 |
Zymeworks Inc. |
ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS
|
|
DK3334747T5
(da)
|
2015-08-13 |
2024-10-07 |
Amgen Inc |
Ladet dybdefiltrering af antigenbindende proteiner
|
|
US10730842B2
(en)
|
2015-09-03 |
2020-08-04 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Small molecule inhibitors of DYRK1A and uses thereof
|
|
BR112018004296B1
(pt)
|
2015-09-04 |
2020-05-05 |
Primatope Therapeutics Inc |
anticorpos anti-cd40 humanizados e usos dos mesmos
|
|
WO2017062920A1
(en)
|
2015-10-07 |
2017-04-13 |
Chopra Sunandini |
Nanoparticles with ph triggered drug release
|
|
CN107207608B
(zh)
|
2015-10-30 |
2021-05-11 |
江苏众红生物工程创药研究院有限公司 |
双特异性抗体、其制备方法和用途
|
|
KR102847348B1
(ko)
|
2015-11-25 |
2025-08-19 |
주식회사 리가켐바이오사이언스 |
펩타이드 그룹을 포함하는 접합체 및 이와 관련된 제조방법
|
|
AU2016359230B2
(en)
|
2015-11-25 |
2020-04-23 |
Ligachem Biosciences Inc. |
Conjugates comprising self-immolative groups and methods related thereto
|
|
AU2016359235B2
(en)
|
2015-11-25 |
2022-09-15 |
Ligachem Biosciences Inc. |
Antibody-drug conjugates comprising branched linkers and methods related thereto
|
|
BR112018012180A2
(pt)
|
2015-12-17 |
2018-12-04 |
Psioxus Therapeutics Ltd |
vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
|
|
US20180291114A1
(en)
|
2015-12-17 |
2018-10-11 |
University Of Maryland, Baltimore County |
Recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression
|
|
MX2018008345A
(es)
|
2016-01-11 |
2018-12-06 |
Univ Leland Stanford Junior |
Proteínas quiméricas y métodos de inmunoterapia.
|
|
US10905727B2
(en)
|
2016-01-14 |
2021-02-02 |
Intrexon Actobiotics N.V. |
Compositions and methods for the treatment of type 1 diabetes
|
|
EP3192810A1
(en)
|
2016-01-14 |
2017-07-19 |
Deutsches Krebsforschungszentrum |
Psma binding antibody and uses thereof
|
|
US20220280440A1
(en)
|
2016-01-15 |
2022-09-08 |
Universidad De Chile |
Method for the manufacture of a dosage form with mucoadhesive properties for buccal administration of biologics
|
|
WO2017124084A1
(en)
|
2016-01-15 |
2017-07-20 |
University Of Maryland, College Park |
Endo-s2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins
|
|
MA55746A
(fr)
|
2016-01-21 |
2022-03-02 |
Novartis Ag |
Molécules multispécifiques ciblant cll-1
|
|
JOP20170017B1
(ar)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
|
EP3416981A1
(en)
|
2016-02-18 |
2018-12-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor
|
|
WO2017143259A1
(en)
|
2016-02-19 |
2017-08-24 |
Dignity Health |
Antibody fusion protein and related compositions for targeting cancer
|
|
WO2017160717A2
(en)
|
2016-03-15 |
2017-09-21 |
Memorial Sloan Kettering Cancer Center |
Method of treating diseases using kinase modulators
|
|
EP3439658B1
(en)
|
2016-04-04 |
2021-11-24 |
ChemoCentryx, Inc. |
Soluble c5ar antagonists
|
|
US11332544B2
(en)
|
2016-04-21 |
2022-05-17 |
Merck Sharp & Dohme Corp. |
Glycan-based antibody-drug conjugates
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448427A1
(en)
|
2016-04-29 |
2019-03-06 |
CureVac AG |
Rna encoding an antibody
|
|
US11339225B2
(en)
|
2016-05-12 |
2022-05-24 |
Asclepius (Suzhou) Technology Company Group, Co., Ltd. |
Bispecific antigen-binding construct and preparation method and use thereof
|
|
CN107365387B
(zh)
|
2016-05-12 |
2022-03-15 |
阿思科力(苏州)生物科技有限公司 |
一种双特异性抗原结合构建体及其制备方法和应用
|
|
US11414491B2
(en)
|
2016-05-18 |
2022-08-16 |
Mayo Foundation For Medical Education And Research |
Targeting PD-L1 on tumor cells
|
|
US10865230B2
(en)
|
2016-05-27 |
2020-12-15 |
Altor Bioscience, Llc |
Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
|
|
IT201800000534A1
(it)
|
2018-01-03 |
2019-07-03 |
|
Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
|
|
US20210347901A9
(en)
|
2016-06-27 |
2021-11-11 |
Agomab Therapeutics |
Methods for promoting pancreatic islet cell growth
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
WO2018014001A1
(en)
|
2016-07-14 |
2018-01-18 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
|
CN109563503B
(zh)
|
2016-07-26 |
2023-09-29 |
静冈县 |
抗b7-h4抗体
|
|
WO2018028449A1
(en)
|
2016-08-08 |
2018-02-15 |
Beigene, Ltd. |
Method for predicting efficacy of immune checkpoint inhibitors in cancer patients
|
|
CN109715819A
(zh)
|
2016-08-10 |
2019-05-03 |
马里兰大学帕克分校 |
设计者α1,6-岩藻糖苷酶突变体实现完整N-糖肽和N-糖蛋白的直接核心岩藻糖基化
|
|
US11123438B2
(en)
|
2016-08-19 |
2021-09-21 |
Ampsource Biopharma Shanghai Inc. |
Linker peptide for constructing fusion protein
|
|
WO2018037416A1
(en)
|
2016-08-25 |
2018-03-01 |
Yeda Research And Development Co. Ltd. |
Methods and compositions for treating autoimmune diseases
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
CN116617387A
(zh)
|
2016-08-29 |
2023-08-22 |
迪赞纳生命科学公开有限公司 |
抗cd3抗体制剂
|
|
WO2018044914A1
(en)
|
2016-08-29 |
2018-03-08 |
Hackensack University Medical Center |
Methods for treating an immune disorder-related disease by reducing autoreactivity in a t cell compartment
|
|
IL303187A
(en)
|
2016-08-29 |
2023-07-01 |
Akamis Bio Ltd |
Adenovirus with bispecific T cell activator
|
|
AU2017321609C1
(en)
|
2016-08-30 |
2023-11-09 |
Dana-Farber Cancer Institute, Inc. |
Drug delivery compositions and uses thereof
|
|
JP2019526579A
(ja)
|
2016-09-01 |
2019-09-19 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ |
Ｔ細胞癌を標的とする為の方法及び組成物
|
|
CN118813511A
(zh)
|
2016-09-02 |
2024-10-22 |
英特瑞克斯顿阿克图比奥帝克斯有限公司 |
稳定表达il-10和胰岛素的遗传修饰的细菌
|
|
RU2021128415A
(ru)
|
2016-09-06 |
2021-11-08 |
Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч |
Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
|
|
EP3504234A4
(en)
|
2016-09-29 |
2020-12-02 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
CONSTRUCTIONS OF HETERODIMERIC IMMUNOGLOBULINS AND THEIR PREPARATION PROCESSES
|
|
EP3522918A1
(en)
|
2016-10-06 |
2019-08-14 |
Amgen Inc. |
Reduced viscosity protein pharmaceutical formulations
|
|
CN106632681B
(zh)
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
WO2018072025A1
(en)
|
2016-10-19 |
2018-04-26 |
The Governing Council Of The University Of Toronto |
Cd133-binding agents and uses thereof
|
|
CA3042031A1
(en)
|
2016-10-27 |
2018-05-03 |
The Trustees Of Columbia University In The City Of New York |
Immunosuppressive mesenchymal cells and methods for forming same
|
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
GB201622044D0
(en)
|
2016-12-22 |
2017-02-08 |
Ucl Business Plc |
T cell-targeted T cells
|
|
KR102085798B1
(ko)
|
2016-12-28 |
2020-03-06 |
주식회사 인투셀 |
베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
|
|
WO2018120842A1
(zh)
|
2016-12-30 |
2018-07-05 |
上海欣百诺生物科技有限公司 |
一种双功能分子及其应用
|
|
WO2018120843A1
(zh)
|
2016-12-30 |
2018-07-05 |
上海近岸生物科技有限公司 |
一种三功能分子及其应用
|
|
US11046768B2
(en)
|
2017-01-27 |
2021-06-29 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
|
WO2018156735A1
(en)
|
2017-02-22 |
2018-08-30 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bispecific antibody for cancer immunotherapy
|
|
WO2018178123A1
(en)
|
2017-03-29 |
2018-10-04 |
Glycotope Gmbh |
BISPECIFIC MUC-1 x PD-L1 ANTIBODIES
|
|
KR102367658B1
(ko)
|
2017-03-29 |
2022-02-25 |
타이페이 메디컬 유니이버시티 |
항원 특이적 t 세포 및 그의 용도
|
|
SG11201909160WA
(en)
|
2017-04-11 |
2019-10-30 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
US12378297B2
(en)
|
2017-04-14 |
2025-08-05 |
The General Hospital Corporation |
Chimeric antigen receptor T cells targeting the tumor microenvironment
|
|
CN108728465A
(zh)
|
2017-04-14 |
2018-11-02 |
深圳新诺微环生物科技有限公司 |
一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
AU2018269370B2
(en)
|
2017-05-16 |
2025-06-05 |
The Johns Hopkins University |
Manabodies and methods of using
|
|
AU2018290272A1
(en)
|
2017-06-21 |
2020-01-30 |
Gsbio, Llc |
Heterodimeric bispecific antibodies
|
|
CN120682290A
(zh)
|
2017-07-04 |
2025-09-23 |
尹图赛利有限公司 |
包含可裂解接头的化合物及其用途
|
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
|
US20190038733A1
(en)
|
2017-08-10 |
2019-02-07 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
|
US20200181264A1
(en)
|
2017-08-11 |
2020-06-11 |
City Of Hope |
Bispecific antigen-binding molecule
|
|
MX2020002611A
(es)
|
2017-09-07 |
2020-07-13 |
Univ Res Inst Inc Augusta |
Activador especifico de akt3 y usos del mismo.
|
|
PL3954384T3
(pl)
|
2017-09-08 |
2025-10-27 |
Diamyd Medical Ab |
Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy
|
|
US20200281976A1
(en)
|
2017-10-04 |
2020-09-10 |
City Of Hope |
Prevention and treatment of gvhd and autoimmune diseases
|
|
CN117721084A
(zh)
|
2017-10-12 |
2024-03-19 |
美商生物细胞基因治疗有限公司 |
靶向多种抗原的复合嵌合抗原受体（cCAR）及其组成和使用方法
|
|
FR3072880A1
(fr)
|
2017-10-30 |
2019-05-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Formulation liposomale et son utilisation en therapie anti-tumorale
|
|
JP7404252B2
(ja)
|
2017-11-08 |
2023-12-25 |
ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド |
生体分子のコンジュゲートおよびその使用
|
|
US20210380641A1
(en)
|
2017-11-09 |
2021-12-09 |
University Of Washington |
Self-assembling protein structures and components thereof
|
|
US12098162B2
(en)
|
2017-11-13 |
2024-09-24 |
Extremochem, Lda |
Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules
|
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
|
MX2020006460A
(es)
|
2017-12-22 |
2020-11-06 |
Chemocentryx Inc |
Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
|
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
|
TWI890481B
(zh)
|
2018-02-09 |
2025-07-11 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
WO2019157533A1
(en)
|
2018-02-12 |
2019-08-15 |
The General Hospital Corporation |
Chimeric antigen receptors targeting the tumor microenvironment
|
|
EP3759235B1
(en)
|
2018-02-27 |
2025-02-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Classifier for identification of robust sepsis subtypes
|
|
GB201805329D0
(en)
|
2018-03-30 |
2018-05-16 |
Univ Leuven Kath |
Biomakers for diabetes therapy
|
|
BR112020019822A2
(pt)
|
2018-04-02 |
2021-03-16 |
Chemocentryx, Inc. |
Profármacos de antagonistas bicíclicos fundidos de c5ar
|
|
WO2019195535A1
(en)
|
2018-04-05 |
2019-10-10 |
Novartis Ag |
Trispecific binding molecules against cancers and uses thereof
|
|
US10633458B2
(en)
|
2018-04-10 |
2020-04-28 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
|
US20210113519A1
(en)
|
2018-04-17 |
2021-04-22 |
Carnegie Mellon University |
Compositions and Methods for Modulating Permeability of Biological Barriers
|
|
US12404512B2
(en)
|
2018-05-01 |
2025-09-02 |
Ambrx, Inc. |
Method for optimizing antibody expression
|
|
IT201800005182A1
(it)
|
2018-05-09 |
2019-11-09 |
|
siRNA contro la variante C1858T del gene PTPN22
|
|
AU2019269361C1
(en)
|
2018-05-14 |
2025-06-12 |
Children's Research Institute, Children's National Medical Center |
Anti-CD24 compositions and uses thereof
|
|
UA130542C2
(uk)
|
2018-05-16 |
2026-03-18 |
Янссен Байотек, Інк. |
Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
|
|
EP3569617A1
(en)
|
2018-05-18 |
2019-11-20 |
Trion Research GmbH |
Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
|
|
US12269863B2
(en)
|
2018-05-23 |
2025-04-08 |
Manysmart Therapeutics, Inc. |
Bispecific T cell engager and uses thereof
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
EP3802798A4
(en)
|
2018-05-31 |
2022-05-11 |
Washington University |
CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) FOR TREATMENT OF CANCER
|
|
EP3801568A4
(en)
|
2018-05-31 |
2022-03-16 |
Washington University |
GENOMIC-EDITED INVARIANT NATURAL KILLER T CELLS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIES
|
|
EP3802595A1
(en)
|
2018-06-07 |
2021-04-14 |
OncoOne Research & Development GmbH |
Anti-oxmif/anti-cd3 antibody for cancer treatment
|
|
WO2020001344A1
(en)
|
2018-06-29 |
2020-01-02 |
Beijing Biocytogen Co., Ltd |
ANTI-CD3e ANTIBODIES AND USES THEREOF
|
|
CA3103374A1
(en)
|
2018-06-29 |
2020-01-02 |
Krystal Biotech, Inc. |
Compositions and methods for antibody delivery
|
|
US20210261646A1
(en)
|
2018-07-03 |
2021-08-26 |
Sotio, LLC |
Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
|
|
JP7482122B2
(ja)
|
2018-07-03 |
2024-05-13 |
アイエフエム デュー インコーポレイテッド |
Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
|
|
EP3820571A1
(en)
|
2018-07-10 |
2021-05-19 |
University of Connecticut |
Reagents and methods for treating cancer and autoimmune disease
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
EP3829636A1
(en)
|
2018-07-27 |
2021-06-09 |
NGM Biopharmaceuticals, Inc. |
Use of glucagon receptor antagonists with immunotherapeutic agent
|
|
CN113286811B
(zh)
|
2018-07-30 |
2024-12-06 |
南加利福尼亚大学 |
改善过继性细胞疗法的效力和安全性
|
|
EP4548924A3
(en)
|
2018-08-09 |
2025-08-13 |
Duke University |
Enhanced delivery of drugs and other compounds to the brain and other tissues
|
|
JP7456638B2
(ja)
|
2018-08-14 |
2024-03-27 |
ソティオ，リミティド ライアビリティ カンパニー |
クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用
|
|
MX2021002301A
(es)
|
2018-08-28 |
2021-04-28 |
Ambrx Inc |
Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
|
|
KR20210056377A
(ko)
|
2018-09-07 |
2021-05-18 |
소티오, 엘엘씨 |
세포내 락테이트 농도를 조절하는 트랜스 대사 분자와 조합된 키메라 수용체 폴리펩타이드 및 이의 치료 용도
|
|
WO2020053301A1
(en)
|
2018-09-11 |
2020-03-19 |
Ichnos Sciences S.A. |
Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents
|
|
WO2020056170A1
(en)
|
2018-09-12 |
2020-03-19 |
Fred Hutchinson Cancer Research Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
|
WO2020056037A1
(en)
|
2018-09-13 |
2020-03-19 |
Board Of Regents Of The University Of Nebraska |
Biomarkers for type 1 diabetes
|
|
US11066476B2
(en)
|
2018-09-14 |
2021-07-20 |
Shanghai tongji hospital |
Asymmetric bispecific antibody
|
|
WO2020081885A1
(en)
|
2018-10-18 |
2020-04-23 |
The Regents Of The University Of California |
Combination therapies for treatment of inflammatory diseases
|
|
EP3870217A4
(en)
|
2018-10-22 |
2022-08-31 |
Icellkealex Therapeutics LLC |
MUTANT VACCINIA VIRUSES AND USE THEREOF
|
|
US20220008533A1
(en)
|
2018-10-31 |
2022-01-13 |
Tiziana Life Sciences Plc |
Composition and methods of treating inflammatory and autoimmune diseases
|
|
JP7410143B2
(ja)
|
2018-11-01 |
2024-01-09 |
山▲東▼新▲時▼代▲薬▼▲業▼有限公司 |
二重特異性抗体及びその用途
|
|
WO2020092743A2
(en)
|
2018-11-01 |
2020-05-07 |
Memorial Sloan Kettering Cancer Center |
Methods of treating diseases using kinase modulators
|
|
TWI850282B
(zh)
|
2018-11-27 |
2024-08-01 |
香港商弘年發展有限公司 |
用於治療癌症之質體建構體和使用方法
|
|
JP2022510218A
(ja)
|
2018-11-30 |
2022-01-26 |
メモリアル スローン ケタリング キャンサー センター |
ヘテロ二量体四価特異性抗体およびこれらの使用
|
|
US20210386680A1
(en)
|
2018-12-06 |
2021-12-16 |
Board Of Regents, The University Of Texas System |
Selectively cleavable therapeutic nanoparticles
|
|
WO2020123806A1
(en)
|
2018-12-14 |
2020-06-18 |
Beth Israel Deaconess Medical Center. Inc. |
Modulation of pd-1
|
|
CA3120466A1
(en)
|
2018-12-14 |
2020-06-18 |
Fred Hutchinson Cancer Research Center |
Transferrin receptor targeting peptides
|
|
CN121405815A
(zh)
|
2018-12-19 |
2026-01-27 |
希望之城 |
Baff-r双特异性t细胞衔接子抗体
|
|
WO2020141459A1
(en)
|
2019-01-03 |
2020-07-09 |
Intocell, Inc. |
Compounds comprising cleavable linker and uses thereof
|
|
KR20210099658A
(ko)
|
2019-01-03 |
2021-08-12 |
주식회사 인투셀 |
절단가능 링커를 포함하는 화합물 및 이의 용도
|
|
US20220119478A1
(en)
|
2019-01-15 |
2022-04-21 |
Caerus Therapeutics, Corp. |
Advanced chimeric antigen receptor vectors for targeting solid tumors
|
|
EP3911371A4
(en)
|
2019-01-18 |
2023-04-26 |
University of Southern California |
METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY
|
|
JP7680358B2
(ja)
|
2019-01-30 |
2025-05-20 |
ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー |
癌抗原を標的とするｄｎａコード化二重特異性ｔ細胞エンゲージャーおよび癌治療薬における使用方法
|
|
US20220144916A1
(en)
|
2019-02-12 |
2022-05-12 |
Board Of Regents, The University Of Texas System |
High affinity engineered t-cell receptors targeting cmv infected cells
|
|
WO2020166592A1
(ja)
|
2019-02-13 |
2020-08-20 |
大日本住友製薬株式会社 |
ヘミアスタリン誘導体とその抗体薬物複合体
|
|
CN113646334B
(zh)
|
2019-02-20 |
2025-09-16 |
国家儿童医院研究所 |
癌症靶向的、病毒编码的、可调节的t细胞（catvert）或nk细胞（catvern）接头
|
|
WO2020168554A1
(zh)
|
2019-02-22 |
2020-08-27 |
武汉友芝友生物制药有限公司 |
改造的Fc片段，包含其的抗体及其应用
|
|
CN112703013B
(zh)
|
2019-02-22 |
2022-09-30 |
武汉友芝友生物制药股份有限公司 |
Cd3抗原结合片段及其应用
|
|
US20220143291A1
(en)
|
2019-02-26 |
2022-05-12 |
Qualigen Inc. |
Whole blood treatment device and methods of removing target agents from whole blood
|
|
EP3938400B1
(en)
|
2019-03-11 |
2025-07-30 |
Memorial Sloan Kettering Cancer Center |
Cd22 antibodies and methods of using the same
|
|
CN113906140B
(zh)
|
2019-03-18 |
2025-01-28 |
路德维格癌症研究院 |
A2/ny-eso-1特异性t细胞受体及其用途
|
|
CN109776683B
(zh)
|
2019-03-19 |
2020-04-07 |
益科思特(北京)医药科技发展有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
US20220177583A1
(en)
|
2019-03-20 |
2022-06-09 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|
|
US12404341B2
(en)
|
2019-03-21 |
2025-09-02 |
Agency For Science, Technology And Research |
Glypican-3 (GPC-3) antibodies
|
|
KR102650991B1
(ko)
|
2019-03-25 |
2024-03-27 |
(주)알테오젠 |
인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
|
|
WO2020191486A1
(en)
|
2019-03-27 |
2020-10-01 |
National Research Council Of Canada |
Antigen-binding agents that specifically bind epidermal growth factor receptor variant iii
|
|
CN120192414A
(zh)
|
2019-04-03 |
2025-06-24 |
建新公司 |
具有降低的断裂的抗αβTCR结合多肽
|
|
CA3136251A1
(en)
|
2019-04-08 |
2020-10-15 |
Memorial Sloan Kettering Cancer Center |
Cd19 antibodies and methods of using the same
|
|
EP3952916A1
(en)
|
2019-04-11 |
2022-02-16 |
Sony Group Corporation |
Programmable polymeric drugs
|
|
CN113905766A
(zh)
|
2019-04-11 |
2022-01-07 |
索尼集团公司 |
可编程的聚合药物
|
|
WO2020210843A2
(en)
|
2019-04-12 |
2020-10-15 |
The Johns Hopkins University |
Tolerogenic artificial antigen-presenting cells
|
|
EP3952913A4
(en)
|
2019-04-12 |
2023-05-10 |
The Johns Hopkins University |
Tolerogenic artificial antigen-presenting cells
|
|
WO2020214928A1
(en)
|
2019-04-18 |
2020-10-22 |
Five Prime Therapeutics, Inc. |
Bioassay for t-cell co-stimulatory proteins containing fc domains
|
|
US20230075314A1
(en)
|
2019-04-29 |
2023-03-09 |
Voyager Therapeutics, Inc. |
VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
|
|
MX2021013299A
(es)
|
2019-04-30 |
2022-01-31 |
Sitryx Therapeutics Ltd |
Derivados de acido itaconico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable.
|
|
US20220202950A1
(en)
|
2019-05-01 |
2022-06-30 |
Engeneic Molecular Delivery Pty Ltd |
Compositions comprising bacterially derived intact minicells for theranostic applications
|
|
EP3966248A4
(en)
|
2019-05-08 |
2023-04-12 |
Memorial Sloan Kettering Cancer Center |
HUMAN ANTIBODIES TO FEL MUCIN-16 AND THEIR METHODS OF USE
|
|
GB201906685D0
(en)
|
2019-05-13 |
2019-06-26 |
Ultrahuman Six Ltd |
Activatable protein constructs and uses thereof
|
|
WO2020232247A1
(en)
*
|
2019-05-14 |
2020-11-19 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
US20220218818A1
(en)
|
2019-06-03 |
2022-07-14 |
Immunolux International Corp. |
Smallpox vaccine and stem cells for treatment of disease
|
|
JP2022535924A
(ja)
|
2019-06-06 |
2022-08-10 |
ジャナックス セラピューティクス，インク． |
腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法
|
|
RS66218B1
(sr)
|
2019-07-01 |
2024-12-31 |
Tonix Pharma Ltd |
Anti-cd154 antitela i njihove upotrebe
|
|
EP3994158A1
(en)
|
2019-07-03 |
2022-05-11 |
Codiak BioSciences, Inc. |
Extracellular vesicles targeting t cells and uses thereof
|
|
CA3148210A1
(en)
|
2019-07-22 |
2021-01-28 |
University Of Florida Research Foundation, Incorporated |
Multimeric protein domains for multifunctionality and enhanced secretion of therapeutic proteins
|
|
GB201910651D0
(en)
|
2019-07-25 |
2019-09-11 |
Autolus Ltd |
Virus-like particle
|
|
US20210130464A1
(en)
|
2019-07-30 |
2021-05-06 |
Provention Bio, Inc. |
Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors
|
|
TR201911542A2
(tr)
|
2019-07-30 |
2021-02-22 |
Bogazici Ueniversitesi |
Anti̇kor-poli̇mer konjugatlari
|
|
MX2022001080A
(es)
|
2019-07-30 |
2022-04-20 |
Provention Bio Inc |
Metodos y composiciones para reducir la inmunogenicidad mediante inhibidores de celulas b no agotadores.
|
|
CN112390882A
(zh)
|
2019-08-19 |
2021-02-23 |
杨洋 |
靶向cd3和cd20的双特异性抗体及其应用
|
|
CA3148179A1
(en)
|
2019-08-20 |
2021-02-25 |
Bruce J. Mccreedy Jr. |
Lymphodepletion dosing regimens for cellular immunotherapies
|
|
JP7748935B2
(ja)
|
2019-08-27 |
2025-10-03 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
ＩＬ１３Ｒα２陽性ヒト腫瘍およびイヌ腫瘍を処置するための合成ＣＡＲ
|
|
US20220281998A1
(en)
|
2019-08-28 |
2022-09-08 |
Azusapharma Sciences, Inc. |
Bifidobacterium spp. expressing and secreting diabody-type bsab
|
|
CA3149583A1
(en)
|
2019-08-30 |
2021-03-04 |
Shattuck Labs, Inc. |
Chimeric proteins in autoimmunity
|
|
US20220306735A1
(en)
|
2019-08-30 |
2022-09-29 |
University Of Kansas |
Compositions including igg fc mutations and uses thereof
|
|
GB201912681D0
(en)
|
2019-09-04 |
2019-10-16 |
Eth Zuerich |
Bispecific binding agent that binds to cd117/c-kit and cd3
|
|
CN112480263A
(zh)
|
2019-09-12 |
2021-03-12 |
普米斯生物技术(苏州)有限公司 |
一种双特异t细胞激活器活化t细胞的设计及其应用
|
|
EP3791931A1
(en)
|
2019-09-13 |
2021-03-17 |
Ichnos Sciences SA |
Bispecific antibodies for the treatment of solid tumors
|
|
KR102081418B1
(ko)
|
2019-09-24 |
2020-05-26 |
주식회사 이뮤니스바이오 |
말초혈액단핵구 유래 조절 t 세포 배양용 조성물 및 이를 이용한 조절 t 세포 배양방법
|
|
US20220348660A1
(en)
|
2019-10-02 |
2022-11-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of adult t-cell leukemia/lymphoma
|
|
AU2020361622A1
(en)
|
2019-10-10 |
2022-04-28 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Oncolytic viruses that express multi-specific immune cell engagers
|
|
KR20210043475A
(ko)
|
2019-10-10 |
2021-04-21 |
주식회사 와이바이오로직스 |
다중 특이적 융합 단백질 및 이의 용도
|
|
JP2023500277A
(ja)
|
2019-11-05 |
2023-01-05 |
イェダ リサーチ アンド デベロップメント カンパニー リミテッド |
Ｔ細胞媒介性自己免疫疾患の治療におけるベト細胞の使用
|
|
WO2021092672A1
(en)
|
2019-11-12 |
2021-05-20 |
Iprogen Biotech Inc. |
Antibody-payload conjugates with enhanced delivery domain and uses thereof
|
|
KR20220108783A
(ko)
|
2019-12-02 |
2022-08-03 |
주식회사 인투셀 |
분자 접합과 관련된 조성물 및 방법
|
|
CN113185611A
(zh)
|
2019-12-05 |
2021-07-30 |
启愈生物技术(上海)有限公司 |
含有肿瘤相关抗原taa抗体的三功能融合蛋白及其应用
|
|
EP4069735A1
(en)
|
2019-12-06 |
2022-10-12 |
OncoOne Research & Development GmbH |
Anti-oxmif/anti-cd3 bispecific antibody constructs
|
|
CN115023422A
(zh)
|
2019-12-12 |
2022-09-06 |
德国费森尤斯卡比有限公司 |
糖基化多肽
|
|
US20230023615A1
(en)
|
2019-12-13 |
2023-01-26 |
Dnalite Therapeutics, Inc. |
Compositions and methods for biological delivery vehicles
|
|
CN115023441A
(zh)
|
2019-12-18 |
2022-09-06 |
特诺福尔股份有限公司 |
与cd38结合的重链抗体
|
|
EP4076523A1
(en)
|
2019-12-18 |
2022-10-26 |
Janssen Biotech, Inc. |
Materials and methods for in vivo biological targeting
|
|
MX2022007846A
(es)
|
2019-12-23 |
2022-07-19 |
Sitryx Therapeutics Ltd |
Derivados carboxi con propiedades antiinflamatorias.
|
|
IL294441A
(en)
|
2019-12-31 |
2022-09-01 |
Fred Hutchinson Cancer Center |
Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites
|
|
WO2021144315A1
(en)
|
2020-01-13 |
2021-07-22 |
Synaffix B.V. |
Conjugates of antibodies an immune cell engagers
|
|
WO2021146328A1
(en)
|
2020-01-13 |
2021-07-22 |
Aptevo Research And Development Llc |
Formulations for protein therapeutics
|
|
AU2021208642B2
(en)
|
2020-01-17 |
2025-06-05 |
Immunelogic Therapeutics, Inc. |
Pro-antibody that reduces off-target toxicity
|
|
JP7789002B2
(ja)
|
2020-01-29 |
2025-12-19 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
|
|
WO2021163097A1
(en)
|
2020-02-14 |
2021-08-19 |
Chang Gung Memorial Hospital |
Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics
|
|
EP3865513A1
(en)
|
2020-02-17 |
2021-08-18 |
Fundación Para La Investigación Biomédica Del Hospital 12 De Octubre |
Anti-cd19/anti-cd3 bispecific antibody, t cells secreting the same, method of preparation and use thereof
|
|
JP2023515196A
(ja)
|
2020-02-27 |
2023-04-12 |
フェインズ セラピューティクス，インコーポレーテッド |
脂肪酸分子とコンジュゲートされた抗体及びその使用
|
|
CN113321738A
(zh)
|
2020-02-27 |
2021-08-31 |
启愈生物技术(上海)有限公司 |
肿瘤靶向、抗cd3和t细胞激活三功能融合蛋白及其应用
|
|
AU2021236302A1
(en)
|
2020-03-12 |
2022-10-20 |
Immune-Onc Therapeutics, Inc. |
Novel anti-LILRB4 antibodies and derivative products
|
|
AU2021239929A1
(en)
|
2020-03-16 |
2022-10-13 |
Crispr Therapeutics Ag |
T-cell bispecific binding proteins
|
|
IL296566A
(en)
|
2020-03-23 |
2022-11-01 |
Cytoarm Co Ltd |
Bi-specific antibodies for use in producing armed immune cells
|
|
CN115297932A
(zh)
|
2020-03-31 |
2022-11-04 |
弗莱德哈钦森癌症中心 |
抗cd33抗体和其用途
|
|
CA3173205A1
(en)
|
2020-03-31 |
2021-10-07 |
Roland B. WALTER |
Human anti-cd33 antibodies and uses thereof
|
|
CN115867275A
(zh)
|
2020-04-13 |
2023-03-28 |
大学健康网络 |
治疗细胞因子释放综合征的方法
|
|
US20230193205A1
(en)
|
2020-04-19 |
2023-06-22 |
Figene, Llc |
Gene modified fibroblasts for therapeutic applications
|
|
CN113527510A
(zh)
|
2020-04-22 |
2021-10-22 |
上海交通大学 |
融合蛋白分子及其制备方法和用途
|
|
EP4139347A4
(en)
|
2020-04-24 |
2024-06-05 |
Memorial Sloan Kettering Cancer Center |
Anti-cd3 antibodies and uses thereof
|
|
BR112022021992A2
(pt)
|
2020-04-30 |
2023-01-03 |
Arch Oncology Inc |
Método de tratamento de câncer em um sujeito em necessidade do mesmo
|
|
AU2021262864A1
(en)
|
2020-04-30 |
2022-11-17 |
Children's Medical Center Corporation |
Antibodies specific to ABCB5 and uses thereof
|
|
US20210349094A1
(en)
|
2020-05-11 |
2021-11-11 |
Musc Foundation For Research Development |
Detection of autoreactive fecal immunoglobulin a (iga) for diagnosis of lupus
|
|
WO2021243206A1
(en)
|
2020-05-29 |
2021-12-02 |
Exosome Diagnostics, Inc. |
Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection
|
|
IL298999A
(en)
|
2020-06-11 |
2023-02-01 |
Provention Bio Inc |
Methods and compositions for the prevention of type 1 diabetes
|
|
MX2022015498A
(es)
|
2020-06-11 |
2023-01-24 |
Tizona Therapeutics |
Captadores de celulas inmunitarias biespecificas con especificidad de union para hla-g y otro antigeno.
|
|
US20230312742A1
(en)
|
2020-06-17 |
2023-10-05 |
Y-Mabs Therapeutics, Inc. |
CD38 antibodies for the treatment of human diseases
|
|
EP4182447A4
(en)
|
2020-07-14 |
2024-10-23 |
Ichilov Tech Ltd. |
PSEUDOTYPED VIRUSES WITH CONFIGURATION FOR EXPRESSION OF CAR IN T CELLS
|
|
EP4185616A1
(en)
|
2020-07-24 |
2023-05-31 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
|
WO2022026439A2
(en)
|
2020-07-28 |
2022-02-03 |
Memorial Sloan Kettering Cancer Center |
Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof
|
|
AU2021316042A1
(en)
|
2020-07-29 |
2023-03-30 |
Minerva Biotechnologies Corporation |
Anti-variable MUC1* antibodies and uses thereof
|
|
WO2022026939A2
(en)
|
2020-07-31 |
2022-02-03 |
Soteria Biotherapeutics, Inc. |
Single and dual targeting ligand induced t-cell engager compositions
|
|
EP4192821A1
(en)
|
2020-08-05 |
2023-06-14 |
Sitryx Therapeutics Limited |
Alpha,beta unsaturated methacrylic esters with anti-inflammatory properties
|
|
JP7792395B2
(ja)
|
2020-08-06 |
2025-12-25 |
アブプロ コーポレーション |
抗クローディン１８．２多重特異性抗体及びそれらの使用
|
|
WO2022035888A2
(en)
|
2020-08-10 |
2022-02-17 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Sars-cov-2-neutralizing antibodies, biomarkers to predict protection from re-infection, and high efficiency antibody screening methods
|
|
CN116724051A
(zh)
|
2020-08-10 |
2023-09-08 |
上海寻百会生物技术有限公司 |
用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法
|
|
WO2022036495A1
(en)
|
2020-08-17 |
2022-02-24 |
Utc Therapeutics Inc. |
Lymphocytes-antigen presenting cells co-stimulators and uses thereof
|
|
US11124568B1
(en)
|
2020-08-19 |
2021-09-21 |
Vitruviae LLC |
CD3/CD25 antibodies for neuro-immune diseases
|
|
US20230338495A1
(en)
|
2020-08-19 |
2023-10-26 |
Vitruviae LLC |
Vaccine Compositions and Antibodies For Lyme Disease
|
|
EP4200328A4
(en)
|
2020-08-21 |
2025-02-26 |
The Rockefeller University |
Single-domain antibodies that bind sars-cov-2
|
|
US20240010606A1
(en)
|
2020-08-21 |
2024-01-11 |
Sitryx Therapeutics Limited |
Fumarate derivatives and their medical use
|
|
CN116322763A
(zh)
|
2020-08-27 |
2023-06-23 |
学校法人顺天堂 |
抗切断型突变calr-cd3双特异性抗体及医药组合物
|
|
CN116368152A
(zh)
|
2020-09-13 |
2023-06-30 |
山东博安生物技术股份有限公司 |
通过受体tac技术的膜结合蛋白的下调
|
|
US20230365676A1
(en)
|
2020-09-15 |
2023-11-16 |
University Of Florida Research Foundation, Incorporated |
Cd33 antibodies
|
|
TW202227478A
(zh)
|
2020-09-15 |
2022-07-16 |
德商拜恩迪克公司 |
對細胞靶向遞送的藥劑及方法
|
|
WO2022063302A1
(zh)
|
2020-09-25 |
2022-03-31 |
克莱格医学有限公司 |
免疫细胞活性调节
|
|
EP4217009A4
(en)
|
2020-09-28 |
2025-09-24 |
Navrogen Inc |
COMPOSITION AND USE OF OTHERWISE FORMATTED ANTI-MESOTHELIN ANTIBODIES IN THE TREATMENT OF CANCER
|
|
US20240026012A1
(en)
|
2020-10-09 |
2024-01-25 |
Seattle Children's Hospital (Dba Seattle Children's Research Institute |
Binders and chimeric antigen receptors which specifically bind fibroblast growth factor receptor 4
|
|
WO2022077108A1
(en)
|
2020-10-15 |
2022-04-21 |
Sunnybook Research Institute |
Bispecific constructs for expanding t cells and related methods
|
|
US20220119549A1
(en)
|
2020-10-15 |
2022-04-21 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof
|
|
AU2020472970A1
(en)
|
2020-10-20 |
2023-06-22 |
Halo Therapeutics Ltd |
Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
WO2022090714A1
(en)
|
2020-10-27 |
2022-05-05 |
Sitryx Therapeutics Limited |
Novel compounds
|
|
EP4237408A1
(en)
|
2020-10-29 |
2023-09-06 |
Sitryx Therapeutics Limited |
Itaconic acid derivatives
|
|
EP4237404A1
(en)
|
2020-10-29 |
2023-09-06 |
Sitryx Therapeutics Limited |
Novel compounds
|
|
US20240002539A1
(en)
|
2020-11-03 |
2024-01-04 |
Ab Studio Inc. |
Multispecific antibodies and uses thereof
|
|
US12116411B2
(en)
|
2020-11-03 |
2024-10-15 |
Abzyme Therapeutics Llc |
Antibodies binding to human CD3 at acidic pH
|
|
US20220160895A1
(en)
|
2020-11-05 |
2022-05-26 |
Homology Medicines, Inc. |
Gene therapy methods
|
|
WO2022099032A1
(en)
|
2020-11-06 |
2022-05-12 |
Bioventures, Llc |
T cells and bifunctional protein against human papillomavirus
|
|
WO2022099076A1
(en)
|
2020-11-06 |
2022-05-12 |
Mcmaster University |
Cells comprising t cell-antigen couplers and uses thereof
|
|
US11505607B2
(en)
|
2020-11-13 |
2022-11-22 |
Binhui Biopharmaceutical Co., Ltd. |
Bispecific single-chain antibody, recombinant oncolytic virus for expressing same and virus composition
|
|
WO2022105787A1
(en)
|
2020-11-17 |
2022-05-27 |
Shenzhen Enduring Biotech, Ltd. |
Long acting bi-specific t cell engagers targeting cd3 and cd47
|
|
EP4251283A1
(en)
|
2020-11-27 |
2023-10-04 |
General Nanotherapeutics LLC |
Methods and composition for treatment of immune-mediated diseases
|
|
IL303149A
(en)
|
2020-11-30 |
2023-07-01 |
Fred Hutchinson Cancer Center |
Pd-l1 binding peptides and peptide complexes and methods of use thereof
|
|
JP2023552462A
(ja)
|
2020-12-08 |
2023-12-15 |
ジャナックス セラピューティクス，インク． |
半減期延長組成物および方法
|
|
WO2022125482A1
(en)
|
2020-12-08 |
2022-06-16 |
Memorial Sloan Kettering Cancer Center |
Antibodies to galectin-3 and methods of use thereof
|
|
AU2021396172A1
(en)
|
2020-12-09 |
2023-07-06 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
|
|
GB202019879D0
(en)
|
2020-12-16 |
2021-01-27 |
Ucl Business Ltd |
Polypeptide
|
|
WO2022132929A2
(en)
|
2020-12-16 |
2022-06-23 |
Vera Therapeutics, Inc. |
Multispecific antibody molecules and uses thereof
|
|
WO2022148736A1
(en)
|
2021-01-05 |
2022-07-14 |
Transgene |
Vectorization of muc1 t cell engager
|
|
WO2022159555A1
(en)
|
2021-01-20 |
2022-07-28 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating graft-versus-host disease using glp-2 agonists and analogues thereof
|
|
EP4032910A1
(en)
|
2021-01-22 |
2022-07-27 |
ETH Zurich |
Bispecific binding agent that binds to cd3 and a fluorophore
|
|
AU2022212952A1
(en)
|
2021-01-27 |
2023-08-10 |
Umoja Biopharma, Inc. |
Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
|
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
|
EP4288455A1
(en)
|
2021-02-03 |
2023-12-13 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
JP2024506022A
(ja)
|
2021-02-08 |
2024-02-08 |
シンアフィックス ビー．ブイ． |
多機能性抗体
|
|
JP2024507948A
(ja)
|
2021-02-26 |
2024-02-21 |
フレッド ハッチンソン キャンサー センター |
呼吸器ウイルス感染症に対する防御抗体
|
|
EP4301859A4
(en)
|
2021-03-04 |
2025-05-28 |
Code Biotherapeutics, Inc. |
Enhanced targeting using antibody-oligonucleotide conjugates
|
|
EP4305051A4
(en)
|
2021-03-08 |
2025-06-04 |
Shattuck Labs, Inc. |
CHIMERIC PROTEINS USEFUL IN AUTOIMMUNITY
|
|
GB202103706D0
(en)
|
2021-03-17 |
2021-04-28 |
Ucl Business Ltd |
CD160 binding domain
|
|
WO2022197907A2
(en)
|
2021-03-18 |
2022-09-22 |
Memorial Sloan-Kettering Cancer Center |
Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors
|
|
EP4308163A1
(en)
|
2021-03-19 |
2024-01-24 |
Shenzhen Enduring Biotech, Ltd. |
Pegylated t cell engager with dual specificities to cd3 and cd19
|
|
JP7708453B2
(ja)
|
2021-03-23 |
2025-07-15 |
広州凌騰生物医薬有限公司 |
Ｃｄ３に結合する多重特異性抗原結合タンパク質とその使用方法
|
|
JP2024520444A
(ja)
|
2021-05-24 |
2024-05-24 |
プロヴェンション・バイオ・インコーポレイテッド |
１型糖尿病を治療するための方法
|
|
KR20240023522A
(ko)
|
2021-05-24 |
2024-02-22 |
프로벤션 바이오, 인코포레이티드 |
감염 후 자가면역성 당뇨병을 치료하는 방법
|
|
AU2022341315A1
(en)
|
2021-09-13 |
2024-05-02 |
Provention Bio, Inc. |
Methods and compositions comprising anti-cd3 antibodies and dyrk1a inhibitors for treating diabetes
|
|
AU2022347193A1
(en)
|
2021-09-20 |
2024-05-02 |
David CUTHBERTSON |
Methods for prognosing type 1 diabetes treatments
|
|
CA3256691A1
(en)
|
2022-05-24 |
2023-11-30 |
Provention Bio, Inc. |
METHODS AND COMPOSITIONS TO PREVENT OR DELAY TYPE 1 DIABETES
|
|
EP4532552A4
(en)
|
2022-05-24 |
2025-10-22 |
Provention Bio Inc |
METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES
|
|
WO2024182767A1
(en)
|
2023-03-01 |
2024-09-06 |
Provention Bio, Inc. |
Methods and compositions for treating type 1 diabetes comprising teplizumab and verapamil
|
|
TW202506177A
(zh)
|
2023-03-30 |
2025-02-16 |
美商普泛森生技公司 |
減少外源性胰島素使用之方法
|